A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE,orMetastatic
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Intensity Therapeutics, Inc.
Start Date
November 5, 2024
End Date
October 27, 2029
Administered By
Duke Cancer Institute
Awarded By
Intensity Therapeutics, Inc.
Start Date
November 5, 2024
End Date
October 27, 2029